GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma
Status:
Unknown status
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of High dose of Methotrexate
combined with gemcitabine, pegaspargase and dexamethasone (GAD-M regimen) as first-line
treatment in patients with de novo extranodal NK/T cell lymphoma.